Achieving a Complete Molecular Remission Under Imatinib Therapy Is Associated with a Better Outcome in Chronic Phase Chronic Myeloid Leukaemia Patients On Imatinib Frontline Therapy

被引：0
|
作者：
Etienne, Gabriel [8 ]
Nicolini, Nicolini E. [1 ]
Dulucq, Stephanie
Schmitt, Anna [8 ]
Hayette, Sandrine
Lippert, Eric [2 ]
Tigaud, Isabelle [3 ]
Morisset, Stephane [4 ]
Bureau, Caroline [5 ]
Adiko, Didier [6 ]
Marit, Gerald [7 ]
Reiffers, Josy [8 ]
Mahon, Francois-Xavier [9 ]
机构：
[1] Univ Lyon 1, Hop Edouard Herriot, HCL, F-69365 Lyon, France
[2] Ctr Hosp Univ, Lab Hematol, Bordeaux, France
[3] Ctr Hosp Lyon Sud, Lab Mol Biol & Cytogenet, F-69310 Pierre Benite, France
[4] Ctr Hosp Lyon Sud, Dept Hematol, F-69310 Pierre Benite, France
[5] Polyclin Bordeaux Nord Aquitaine, Bordeaux, France
[6] Hop Robert Boulin, Libourne, France
[7] CHU, Serv Hematol Clin & Therapie Cellulaire, Pessac, France
[8] Univ Victor Segalen Bordeaux, Inst Bergonie, Bordeaux, France
[9] CHU Bordeaux, Dept Hematol, Hop Pellegrin, INSERM 1035, Bordeaux, France
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3754.3754
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3754
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
    Kavanagh, Simon
    Bril, Vera
    Lipton, Jeffrey H.
    BLOOD RESEARCH, 2018, 53 (02) : 172 - 174
  • [32] Evaluation of the Relationship Between Initial Lymphocyte Count and Molecular Response to Imatinib Therapy in Chronic Myeloid Leukaemia Patients
    Serin, Istemi
    Dogu, Mehmet Hilmi
    Cavdar, Vahit Can
    Suyani, Elif
    ISTANBUL MEDICAL JOURNAL, 2020, 21 (06): : 473 - 476
  • [33] Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment
    Colombat, M
    Fort, MP
    Chollet, C
    Marit, G
    Roche, C
    Preudhomme, C
    Reiffers, J
    Praloran, V
    Mahon, FX
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (02): : 162 - 168
  • [34] Imatinib exacerbates hypothyroidism in patients with chronic myeloid leukaemia
    Jackson, C.
    Jackson, C.
    Parapia, L. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 534 - 535
  • [35] Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase
    Malhotra, Hemant
    Sharma, Pratibha
    Malhotra, Bharti
    Bhargava, Shipra
    Jasuja, Sandeep
    Kumar, Madhu
    INDIAN JOURNAL OF MEDICAL RESEARCH, 2015, 142 : 175 - 182
  • [36] Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib
    Heartin, E
    Walkinshaw, S
    Clark, RE
    LEUKEMIA & LYMPHOMA, 2004, 45 (06) : 1307 - 1308
  • [37] Molecular remission to imatinib in patients with chronic myeloid leukaemia (CML) is less durable compared to patients after allografting
    Lange, T
    Bumm, T
    Mueller, M
    Otto, S
    Al-Ali, HK
    Grommisch, L
    Musiol, S
    Franke, C
    Krahl, R
    Niederwieser, DW
    Deininger, MW
    BLOOD, 2004, 104 (11) : 82A - 83A
  • [38] Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy
    Seiichi Okabe
    Tetsuzo Tauchi
    Yuko Ishii
    Daigo Akahane
    Kousuke Nunoda
    Seiko Honda
    Tomoiku Takaku
    Kazuma Ohyashiki
    International Journal of Hematology, 2007, 85 : 173 - 174
  • [39] Weight gain associated with imatinib therapy in patients with chronic myeloid leukemia (CML).
    Ault, P
    Kantarjian, H
    Kaled, S
    Rios, MB
    O'Brien, S
    Cortes, JE
    BLOOD, 2002, 100 (11) : 321B - 321B
  • [40] Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Ishii, Yuko
    Akahane, Daigo
    Nunoda, Kousuke
    Honda, Seiko
    Takaku, Tomoiku
    Ohyashiki, Kazuma
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 85 (02) : 173 - 174
12345